Understanding how Acinetobacter baumannii develops resistance to antibiotics
Reinforcing the barrier: Understanding how cell envelope modifications promote intrinsic antimicrobial tolerance and resistance in Acinetobacter baumannii
This study is looking into how a common germ that can cause infections in hospitals learns to resist antibiotics, so we can find better ways to fight these tough infections.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Texas Dallas NIH-funded |
| Lab location | 1 site (Richardson, United States) |
| Project ID | NIH-11061924 on NIH RePORTER |
What this research studies
This research investigates the mechanisms by which Acinetobacter baumannii, a significant cause of hospital-acquired infections, develops resistance to antibiotics. The team will explore how modifications to the bacterial cell envelope contribute to its ability to tolerate and resist antimicrobial treatments. By examining the interactions between the outer membrane and cell wall, the researchers aim to uncover intrinsic factors that lead to multidrug resistance. This knowledge could inform the development of new strategies to combat these resistant infections.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with hospital-acquired infections caused by Acinetobacter baumannii, particularly those with multidrug-resistant strains.
Not a fit: Patients with infections caused by other types of bacteria or those who are not hospitalized may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatment options for patients suffering from infections caused by antibiotic-resistant Acinetobacter baumannii.
How similar studies have performed: Previous research has shown success in understanding antibiotic resistance mechanisms in other bacteria, suggesting that this approach may yield valuable insights.
Where this research is happening
Richardson, United States
- University of Texas Dallas — Richardson, United States (Active)
Researchers
- Principal investigator: Boll, Joseph Michael — University of Texas Dallas
- Study coordinator: Boll, Joseph Michael
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.